Patient Education Centre

Medical Cannabis

Medical cannabis is a broad term used to refer to any medical products derived from, or related to, cannabis. In legal terminology and the medical field they are often referred to as cannabis-based medicinal products (CBMPs). CBMPs were legalised for use on prescription in November 2018.

There are a number of products that fall into this category, including whole cannabis flower – which can be vaporised, as well as capsules, oils, sprays, and pastilles containing cannabinoids. The main compounds utilised in medical cannabis products are the cannabinoids cannabidiol (CBD) and tetrahydrocannabinol (THC) which have been investigated for their useful therapeutic properties. In addition to cannabinoids, whole cannabis flower or full spectrum extracts of the plant may contain other compounds called terpenes and flavonoids. These compounds are found across all plants and are often responsible for the smell, taste and colour of different plants. There is some research into potential medical properties of these compounds, however this is still an area of growing research.

Currently, Sativex, Nabilone, and Epidyolex are currently the only licensed medical cannabis products in the UK. However, other unlicensed products may also be prescribed in patients where first-line therapies have been unsuccessful.

CBMPs are different from CBD oil available over the counter as all CBMPs are produced to EU Good Manufacturing Practices which ensures consistency in supply and quality. In contrast, CBD oil available on the high street is classified as a novel food and therefore does not have to meet the same stringent regulations regarding its manufacture.

Cannabinoids, THC and CBD

Cannabinoids are compounds that are able to interact with the receptors found in the body’s endocannabinoid system (ECS). The ECS is made up of numerous receptors, cannabinoids and enzymes. The most well studied receptors are known as cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2). CB1 is predominantly found in the brain and is acted upon by the body’s own cannabinoids (endocannabinoids) to regulate emotions, motor coordination and cognition. CB2 is predominantly found in immune cells and activation by endocannabinoids is thought to effect the immune system.

There are over 120 cannabinoids found in the Cannabis plant, the most common being THC and CBD. THC is similar to the endocannabinoids, by having stimulating effects at the CB1 and CB2 receptors. At sufficient doses THC can overstimulate CB1 receptors in the brain resulting in the ‘high’ typically associated with its recreational use. At low doses however, this is not typically experienced.

CBD on the other hand has a diverse role in the ECS. CBD’s main role is thought to be not through direct action at CB1 or CB2 receptors but by inhibiting an enzyme called fatty acid amide hydrolase (FAAH). This enzyme breaks down the body’s main endocannabinoids. By stopping this enzyme from working as it otherwise would it increases the amount of endocannabinoids available to stimulate cannabinoid receptors. However, CBD also works to change the shape of cannabinoid receptors reducing the effects of THC and endocannabinoids. This is thought to be the mechanism by which CBD can alter the effects THC, particularly reducing any associated euphoria or ‘high’.

In addition to their effects on the endocannabinoid system they have indirect and direct effects on receptors that are involved in pain pathways, mood and anxiety levels, inflammation, and movement.